Inclusion Criteria:

          -  Prior histologically confirmed low- or intermediate-risk non-muscle invasive
             urothelial carcinoma of the bladder (NMIBC) defined according to the following
             characteristics:

               -  Low Risk

                    -  Initial tumor with all of the following:

                    -  Solitary tumor

                    -  Ta tumor

                    -  Low-grade

                    -  <3 cm

                    -  No CIS

               -  Intermediate Risk

                  --- All tumors not defined in the two adjacent categories (between the category
                  of low- and high-risk)

               -  High Risk

                    -  T1 tumor

                    -  High-grade

                    -  CIS

                    -  Multiple and recurrent and large (>3 cm) Ta low-grade tumors (all conditions
                       must be met for this point on Ta low-grade tumors)

          -  Documented tumor recurrence as noted in standard of care follow up cystoscopy.

          -  ECOG (WHO) performance status 0-2

          -  Age ≥ 18 years old

          -  Patients must have the following laboratory values:

               -  White blood cell count (WBC) > 3.0 K/mm3

               -  Absolute neutrophil count (ANC) ≥ 1.5 K/mm3

               -  Platelets ≥ 100 K/mm3

               -  Hemoglobin (Hgb) ≥ 9 g/dL

               -  Serum total bilirubin: ≤ 1.5 x ULN

               -  ALT and AST ≤ 3.0 x ULN

               -  Serum calcium < ULN

               -  Serum phosphate < ULN

               -  Serum creatinine ≤ 1.5 x ULN or serum creatinine > 1.5 - 3 x ULN if calculated
                  creatinine clearance (CrCl) is ≥ 30 mL/min using the modified Cockcroft-Gault
                  equation

          -  Patients who give a written informed consent obtained according to local guidelines

        Exclusion Criteria:

          -  Patients with concurrent upper urinary tract (i.e. ureter, renal pelvis) non-invasive
             urothelial carcinoma.

          -  Patients with high grade urothelial carcinoma on their most recent urine cytology.

          -  Patients with another active second malignancy other than non-melanoma skin cancers
             and biochemical relapsed prostate cancer. (Patients that have completed all necessary
             therapy and are considered to be at less than 30% risk of relapse are not considered
             to have an active second malignancy and are eligible for enrollment.)

          -  Patients who have received the last administration of an anti-cancer therapy including
             chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting
             study drug, or who have not recovered from the side effects of such therapy

          -  Patients who have received prior selective fibroblast growth factor receptor targeting
             agents (i.e. pemigatinib, dovitinib, BGJ398, AZD4547, JNJ-42756493, etc.).

          -  Patients who have had radiotherapy ≤ 4 weeks prior to starting study drug, or who have
             not recovered from radiotherapy toxicities

          -  Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or
             intra-pelvic), open biopsy or significant traumatic injury ≤ 4 weeks prior to starting
             study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous
             biopsies or placement of vascular access device ≤ 1 week prior to starting study drug,
             or who have not recovered from side effects of such procedure or injury